ATRA
NASDAQ · Biotechnology
Atara Biotherapeutics Inc
$8.37
-0.44 (-4.99%)
Open$8.69
Previous Close$8.81
Day High$8.71
Day Low$8.34
52W High$19.15
52W Low$3.92
Volume—
Avg Volume42.2K
Market Cap85.72M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-15.9% upside
Current
$8.37
$8.37
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 95.32M | 76.96M | 4.60M |
| Net Income | 25.80M | 18.75M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 29.97M | 22.99M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |